CODE FAST: A quality improvement initiative to reduce door-to-needle times

Journal of NeuroInterventional Surgery

Volumn 8, Issue 7, 2016, Pages 661-664

  Busby, Leslie ^a   Owada, Kumiko ^a   Dhungana, Samish ^a   Zimmermann, Susan ^a   Coppola, Victoria ^a   Ruban, Rebecca ^a   Horn, Christopher ^a   Rochestie, Dustin ^a   Khaldi, Ahmad ^a   Hormes, Joseph T ^b   Gupta, Rishi ^a  

^a WellStar Kennestone Hospital   (United States)

^b Marietta Neurology and Headache Center   (United States)

Author keywords

Stroke; Thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DOOR TO NEEDLE TIMES; FEMALE; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TIME TO TREATMENT; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; UNIVARIATE ANALYSIS; AGE; DIAGNOSTIC IMAGING; EMERGENCY HEALTH SERVICE; FACTUAL DATABASE; FIBRINOLYTIC THERAPY; MIDDLE AGED; NEUROIMAGING; ORGANIZATION AND MANAGEMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEUROIMAGING; PATIENT DISCHARGE; QUALITY IMPROVEMENT; RETROSPECTIVE STUDIES; SEX FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84977636860     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2015-011806     Document Type: Article

References (8)

1. Lees KR, Bluhmki E, von Kummer R, et al., ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703.
2. Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. Stroke 2011;42:2983-9.
3. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311:1632-40.
4. Meretoja A, Strbian D, Mustanoja S, et al. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012;79:306-13.
5. Ford AL, Williams JA, Spencer M, et al. Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis. Stroke 2012;43:3395-8.
6. Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013;81:1071-6.
7. Bhatt A, Shatila A. Neurohospitalists improve door-to-needle times for patients with ischemic stroke receiving intravenous t-PA. Neurohospitalist 2012;2:119-22.
8. Greenberg K, Maxwell CR, Moore KD, et al. Improved door-to-needle times and neurologic outcomes when IV tissue plasminogen activator is administered by emergency physicians with advanced neuroscience training. Am J Emerg Med 2015;33:234-7.